To explore whether DAB2 could be used as a therapeutic target in GC, an AAV- mediated shRNA was constructed, and patient-derived organoid (PDO) model and patient-derived xenografts (PDX) mouse model were adopted (Fig. 6A). This evidence concerns the gene DAB2 and gastric cancer.